Effect	0	6	O
of	7	9	O
thalidomide	10	21	B-Drug_or_compound
affecting	22	31	O
VEGF	32	36	B-Gene_or_gene_product
secretion	37	46	O
,	46	47	O
cell	48	52	O
migration	53	62	O
,	62	63	O
adhesion	64	72	O
and	73	76	O
capillary	77	86	B-Tissue
tube	87	91	I-Tissue
formation	92	101	O
of	102	104	O
human	105	110	B-Organism
endothelial	111	122	B-Cell
EA	123	125	I-Cell
.	125	126	I-Cell
hy	126	128	I-Cell
926	129	132	I-Cell
cells	133	138	I-Cell
.	138	139	O

Angiogenesis	141	153	O
,	153	154	O
new	155	158	O
blood	159	164	B-Multi-tissue_structure
vessel	165	171	I-Multi-tissue_structure
formation	172	181	O
,	181	182	O
is	183	185	O
a	186	187	O
multistep	188	197	O
process	198	205	O
,	205	206	O
precisely	207	216	O
regulated	217	226	O
by	227	229	O
pro	230	233	O
-	233	234	O
angiogenic	234	244	O
cytokines	245	254	O
,	254	255	O
which	256	261	O
stimulate	262	271	O
endothelial	272	283	B-Cell
cells	284	289	I-Cell
to	290	292	O
migrate	293	300	O
,	300	301	O
proliferate	302	313	O
and	314	317	O
differentiate	318	331	O
to	332	334	O
form	335	339	O
new	340	343	O
capillary	344	353	B-Tissue
microvessels	354	366	I-Tissue
.	366	367	O

Excessive	368	377	O
vascular	378	386	B-Multi-tissue_structure
development	387	398	O
and	399	402	O
blood	403	408	B-Multi-tissue_structure
vessel	409	415	I-Multi-tissue_structure
remodeling	416	426	O
appears	427	434	O
in	435	437	O
psoriasis	438	447	O
,	447	448	O
rheumatoid	449	459	O
arthritis	460	469	O
,	469	470	O
diabetic	471	479	O
retinopathy	480	491	O
and	492	495	O
solid	496	501	B-Pathological_formation
tumors	502	508	I-Pathological_formation
formation	509	518	O
.	518	519	O

Thalidomide	520	531	B-Drug_or_compound
[	532	533	O
alpha	533	538	B-Drug_or_compound
-	538	539	I-Drug_or_compound
(	539	540	I-Drug_or_compound
N	540	541	I-Drug_or_compound
-	541	542	I-Drug_or_compound
phthalimido	542	553	I-Drug_or_compound
)	553	554	I-Drug_or_compound
-	554	555	I-Drug_or_compound
glutarimide	555	566	I-Drug_or_compound
]	566	567	O
is	568	570	O
known	571	576	O
to	577	579	O
be	580	582	O
a	583	584	O
potent	585	591	O
inhibitor	592	601	O
of	602	604	O
angiogenesis	605	617	O
,	617	618	O
but	619	622	O
the	623	626	O
mechanism	627	636	O
of	637	639	O
its	640	643	O
inhibitory	644	654	O
action	655	661	O
remains	662	669	O
unclear	670	677	O
.	677	678	O

The	679	682	O
aim	683	686	O
of	687	689	O
the	690	693	O
study	694	699	O
was	700	703	O
to	704	706	O
investigate	707	718	O
the	719	722	O
potential	723	732	O
influence	733	742	O
of	743	745	O
thalidomide	746	757	B-Drug_or_compound
on	758	760	O
the	761	764	O
several	765	772	O
steps	773	778	O
of	779	781	O
angiogenesis	782	794	O
,	794	795	O
using	796	801	O
in	802	804	O
vitro	805	810	O
models	811	817	O
.	817	818	O

We	819	821	O
have	822	826	O
evaluated	827	836	O
the	837	840	O
effect	841	847	O
of	848	850	O
thalidomide	851	862	B-Drug_or_compound
on	863	865	O
VEGF	866	870	B-Gene_or_gene_product
secretion	871	880	O
,	880	881	O
cell	882	886	O
migration	887	896	O
,	896	897	O
adhesion	898	906	O
as	907	909	O
well	910	914	O
as	915	917	O
in	918	920	O
capillary	921	930	B-Tissue
formation	931	940	O
of	941	943	O
human	944	949	B-Organism
endothelial	950	961	B-Cell
cell	962	966	I-Cell
line	967	971	I-Cell
EA	972	974	I-Cell
.	974	975	I-Cell
hy	975	977	I-Cell
926	978	981	I-Cell
.	981	982	O

Thalidomide	983	994	B-Drug_or_compound
at	995	997	O
the	998	1001	O
concentrations	1002	1016	O
of	1017	1019	O
0	1020	1021	O
.	1021	1022	O
01	1022	1024	O
microM	1025	1031	O
and	1032	1035	O
10	1036	1038	O
microM	1039	1045	O
inhibited	1046	1055	O
VEGF	1056	1060	B-Gene_or_gene_product
secretion	1061	1070	O
into	1071	1075	O
supernatants	1076	1088	O
,	1088	1089	O
decreased	1090	1099	O
the	1100	1103	O
number	1104	1110	O
of	1111	1113	O
formed	1114	1120	O
capillary	1121	1130	B-Tissue
tubes	1131	1136	I-Tissue
and	1137	1140	O
increased	1141	1150	O
cell	1151	1155	B-Cell
adhesion	1156	1164	O
to	1165	1167	O
collagen	1168	1176	B-Gene_or_gene_product
.	1176	1177	O

Administration	1178	1192	O
of	1193	1195	O
thalidomide	1196	1207	B-Drug_or_compound
at	1208	1210	O
the	1211	1214	O
concentration	1215	1228	O
of	1229	1231	O
0	1232	1233	O
.	1233	1234	O
01	1234	1236	O
microM	1237	1243	O
increased	1244	1253	O
cell	1254	1258	B-Cell
migration	1259	1268	O
,	1268	1269	O
while	1270	1275	O
at	1276	1278	O
10	1279	1281	O
microM	1282	1288	O
,	1288	1289	O
it	1290	1292	O
decreased	1293	1302	O
cell	1303	1307	B-Cell
migration	1308	1317	O
.	1317	1318	O

Thalidomide	1319	1330	B-Drug_or_compound
in	1331	1333	O
concentrations	1334	1348	O
from	1349	1353	O
0	1354	1355	O
.	1355	1356	O
1	1356	1357	O
microM	1358	1364	O
to	1365	1367	O
10	1368	1370	O
microM	1371	1377	O
did	1378	1381	O
not	1382	1385	O
change	1386	1392	O
cell	1393	1397	B-Cell
proliferation	1398	1411	O
of	1412	1414	O
72	1415	1417	O
-	1417	1418	O
h	1418	1419	O
cell	1420	1424	B-Cell
cultures	1425	1433	I-Cell
.	1433	1434	O

We	1435	1437	O
conclude	1438	1446	O
that	1447	1451	O
anti	1452	1456	O
-	1456	1457	O
angiogenic	1457	1467	O
action	1468	1474	O
of	1475	1477	O
thalidomide	1478	1489	B-Drug_or_compound
is	1490	1492	O
due	1493	1496	O
to	1497	1499	O
direct	1500	1506	O
inhibitory	1507	1517	O
action	1518	1524	O
on	1525	1527	O
VEGF	1528	1532	B-Gene_or_gene_product
secretion	1533	1542	O
and	1543	1546	O
capillary	1547	1556	B-Tissue
microvessel	1557	1568	I-Tissue
formation	1569	1578	O
as	1579	1581	O
well	1582	1586	O
as	1587	1589	O
immunomodulatory	1590	1606	O
influence	1607	1616	O
on	1617	1619	O
EA	1620	1622	B-Cell
.	1622	1623	I-Cell
hy	1623	1625	I-Cell
926	1626	1629	I-Cell
cells	1630	1635	I-Cell
migration	1636	1645	O
and	1646	1649	O
adhesion	1650	1658	O
.	1658	1659	O

